ERBB2 and breast carcinoma: Since the observation of geldanamycin-incurred ErbB2 degradation, different intracellular itineraries and degradation pathways for ubiquitylated ErbB2 have been proposed in ErbB2-positive breast cancer cells exposed to HSP90 inhibitors [11, 21–24].